Advertisement
U.S. markets open in 5 hours 54 minutes
  • S&P Futures

    5,209.25
    -5.50 (-0.11%)
     
  • Dow Futures

    39,222.00
    -1.00 (-0.00%)
     
  • Nasdaq Futures

    18,184.75
    -46.75 (-0.26%)
     
  • Russell 2000 Futures

    2,047.30
    -2.50 (-0.12%)
     
  • Crude Oil

    82.66
    -0.06 (-0.07%)
     
  • Gold

    2,158.80
    -5.50 (-0.25%)
     
  • Silver

    25.16
    -0.11 (-0.44%)
     
  • EUR/USD

    1.0866
    -0.0011 (-0.10%)
     
  • 10-Yr Bond

    4.3400
    0.0000 (0.00%)
     
  • Vix

    14.51
    +0.18 (+1.26%)
     
  • GBP/USD

    1.2707
    -0.0022 (-0.17%)
     
  • USD/JPY

    150.1110
    +1.0130 (+0.68%)
     
  • Bitcoin USD

    64,253.90
    -3,982.71 (-5.84%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,722.55
    -4.87 (-0.06%)
     
  • Nikkei 225

    40,003.60
    +263.20 (+0.66%)
     

XenoPort to continue development of XP23829 after Phase 1 results

XenoPort announced the preliminary results from two Phase 1 studies with XP23829, a novel fumaric acid ester compound that is a prodrug of monomethyl fumarate. Based on the favorable preliminary results from these studies, XenoPort intends to continue to advance the development of XP23829 as a potential treatment for patients with relapsing-remitting multiple sclerosis and/or psoriasis.

Advertisement